159.08
price up icon1.13%   1.77
 
loading
전일 마감가:
$157.31
열려 있는:
$158
하루 거래량:
234.06K
Relative Volume:
1.19
시가총액:
$3.12B
수익:
$152.42M
순이익/손실:
$45.24M
주가수익비율:
63.38
EPS:
2.51
순현금흐름:
$6.97M
1주 성능:
+5.30%
1개월 성능:
+20.10%
6개월 성능:
+31.83%
1년 성능:
+53.52%
1일 변동 폭
Value
$156.91
$161.93
1주일 범위
Value
$149.51
$161.93
52주 변동 폭
Value
$93.58
$161.93

리간드 파마 Stock (LGND) Company Profile

Name
명칭
Ligand Pharmaceuticals Inc
Name
전화
858-550-7500
Name
주소
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Name
직원
68
Name
트위터
@Ligand_LGND
Name
다음 수익 날짜
2025-02-18
Name
최신 SEC 제출 서류
Name
LGND's Discussions on Twitter

LGND을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
LGND
Ligand Pharmaceuticals Inc
159.08 3.02B 152.42M 45.24M 6.97M 2.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

리간드 파마 Stock (LGND) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-10 개시 Stifel Buy
2024-10-03 개시 Oppenheimer Outperform
2024-07-30 개시 RBC Capital Mkts Outperform
2021-04-14 재개 Stephens Overweight
2021-02-04 재확인 H.C. Wainwright Buy
2020-10-06 개시 Barclays Overweight
2020-03-24 다운그레이드 Argus Buy → Hold
2020-03-10 개시 Guggenheim Neutral
2020-02-06 개시 The Benchmark Company Buy
2019-09-19 업그레이드 Barclays Equal Weight → Overweight
2019-06-11 개시 Barclays Equal Weight
2019-05-03 재확인 H.C. Wainwright Buy
2019-03-06 재확인 H.C. Wainwright Buy
2018-10-29 업그레이드 ROTH Capital Neutral → Buy
2018-10-02 재확인 H.C. Wainwright Buy
2018-09-11 재확인 Argus Buy
2018-08-17 개시 Goldman Neutral
2018-08-08 다운그레이드 ROTH Capital Buy → Neutral
2018-06-21 개시 Argus Buy
2017-12-27 재확인 H.C. Wainwright Buy
2017-09-05 재개 H.C. Wainwright Buy
2016-10-05 재확인 H.C. Wainwright Buy
2016-08-05 다운그레이드 Deutsche Bank Hold → Sell
2016-03-11 개시 Sidoti Buy
2016-03-03 개시 H.C. Wainwright Buy
모두보기

리간드 파마 주식(LGND)의 최신 뉴스

pulisher
Aug 20, 2025

Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced - Investing.com

Aug 20, 2025
pulisher
Aug 19, 2025

Ligand to Participate in September Investor Conferences | LGND Stock News - GuruFocus

Aug 19, 2025
pulisher
Aug 19, 2025

Ligand Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2025 - Quiver Quantitative

Aug 19, 2025
pulisher
Aug 19, 2025

Ligand to Participate in September Investor Conferences - Yahoo Finance

Aug 19, 2025
pulisher
Aug 17, 2025

Published on: 2025-08-18 01:20:46 - sundaytimes.kr

Aug 17, 2025
pulisher
Aug 17, 2025

Ligand Pharmaceuticals to offer $400M convertible senior notes in private placement - MSN

Aug 17, 2025
pulisher
Aug 16, 2025

Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionJuly 2025 News Drivers & Daily Growth Stock Tips - beatles.ru

Aug 16, 2025
pulisher
Aug 15, 2025

What to do if you’re stuck in Ligand Pharmaceuticals IncorporatedDividend Hike & AI Forecast for Swing Trade Picks - Newser

Aug 15, 2025
pulisher
Aug 14, 2025

Ligand Pharmaceuticals Incorporated Shows Early Signs of Technical Strength2025 Trading Recap & Free High Accuracy Swing Entry Alerts - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Ligand Pharmaceuticals raises $400mln through convertible senior notes offering. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Ligand Pharma Completes $460M Convertible Notes Offering - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

Ligand Pharmaceuticals completes $460 million convertible notes offering By Investing.com - Investing.com Canada

Aug 14, 2025
pulisher
Aug 14, 2025

Ligand Announces Closing of Convertible Senior Notes Offering - Yahoo Finance

Aug 14, 2025
pulisher
Aug 13, 2025

Detecting support and resistance levels for Ligand Pharmaceuticals IncorporatedWeekly Market Summary & Expert Approved Momentum Ideas - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

US Bancorp DE Purchases 3,301 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Aug 13, 2025
pulisher
Aug 12, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $185.00 - MarketBeat

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Pharmaceuticals shares rise 3.65% intraday after pricing $400 million convertible senior notes offering. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand's $400M Convertible Notes Offering: A Strategic Move for M&A-Driven Growth and Shareholder Value - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Pharmaceuticals Stock (LGND) Opinions on $400M Convertible Notes Offering - Quiver Quantitative

Aug 12, 2025
pulisher
Aug 12, 2025

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Prices $400 Million Convertible Senior Notes Offering - MarketScreener

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Pharmaceuticals Experiences Strong Q2 Earnings with Robust Revenue Growth, Successful Mergers and Investments, and Raised Financial Guidance. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Pharmaceuticals Prices Offering Of $400 Mln Of Senior Notes - Nasdaq

Aug 12, 2025
pulisher
Aug 12, 2025

Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Pharmaceuticals Secures $400M in Convertible Debt Offering - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Pharmaceuticals' Convertible Notes Offering: A Strategic Move for Capital Optimization and Growth - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering | LGND Stock News - GuruFocus

Aug 12, 2025
pulisher
Aug 12, 2025

Ligand Pharmaceuticals prices $400 million convertible notes offering By Investing.com - Investing.com Canada

Aug 12, 2025
pulisher
Aug 11, 2025

Ligand's Convertible Notes Offering: Balancing Dilution Risks and Strategic Flexibility in Biopharma Financing - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030 - Quiver Quantitative

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Secures $400M Convertible Note Deal: Key Terms Reveal 0.75% Rate and $15M Share Buyback - Stock Titan

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand prices $400 million convertible senior notes offering - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Pharmaceuticals Prices $400M Convertible Senior Notes Offering - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - GlobeNewswire Inc.

Aug 11, 2025
pulisher
Aug 11, 2025

LGNDLigand Pharma Latest Stock News & Market Updates - Stock Titan

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Pharmaceuticals Inc. Reports Strong Q2 Earnings - TipRanks

Aug 11, 2025
pulisher
Aug 11, 2025

LGND: Getting In Tune with MedTech - Zacks Small Cap Research

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Pharmaceuticals Plans $400 Million Convertible Senior Notes Offering - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes - Nasdaq

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Pharmaceuticals shares fall 4.06% premarket after announcing a $400 million convertible senior notes offering. - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Announces $400M Convertible Senior Notes Offering Due 2030. - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Pharmaceuticals plans $400 million convertible notes offering By Investing.com - Investing.com Canada

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Pharmaceuticals to Offer $400mln Convertible Senior Notes Due 2030. - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

Ligand Launches Major $400M Convertible Notes Deal with Strategic Share Buyback Plan - Stock Titan

Aug 11, 2025
pulisher
Aug 10, 2025

Analyzing Ligand Pharmaceuticals Incorporated with risk reward ratio chartsMonthly Long-Term Market Recap and Summary - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics - AInvest

Aug 10, 2025
pulisher
Aug 10, 2025

Will Ligand Pharmaceuticals Incorporated Recover After Recent DeclineStable Entry High Return Opportunities in Focus - beatles.ru

Aug 10, 2025
pulisher
Aug 10, 2025

Royal Bank Of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - Defense World

Aug 10, 2025
pulisher
Aug 09, 2025

A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $157 to $185 - 富途牛牛

Aug 09, 2025

리간드 파마 (LGND) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
자본화:     |  볼륨(24시간):